Skip to main content

Advertisement

Table 2 Scores of SF-36 between antiviral-treated CHC patients, Taiwanese general populations, and patients without antiviral therapy

From: Assessment of health-related quality of life in antiviral-treated Taiwanese chronic hepatitis C patients using SF-36 and CLDQ

SF-36 domains & CLDQ General populations (N = 256,A) mean (SD) CHC without antiviral-treated patients (N = 64,B) Mean (SD) Antiviral-treated CHC patients (N = 64,C) Mean (SD) F¸ (post-hoc multiple comparison) t-test
Physical functioning 82.79 (22.16) 71.95 (29.33) 75.86 (21.85) 6.57** (A > B)
Role physical 72.95 (41.34) 66.07 (45.36) 35.94 (44.29) 19.19** (A > C&B > C)
Bodily pain 74.26 (17.97) 80.63 (25.04) 73.30 (22.84) 2.88
General health 64.78 (19.96) 41.84 (28.57) 51.78 (20.99) 32.35** (A > C > B)
Vitality 65.33 (16.80) 60.94 (25.91) 50.00 (25.09) 15.01**(A,B > C)
Social functioning 83.35 (15.98) 81.53 (22.49) 75.23 (24.39) 4.78**(A > C)
Role emotional 79.43 (37.72) 78.11 (37.70) 43.20 (46.66) 22.32** (A,B > C)
Mental health 70.91 (14.77) 71.88 (18.43) 61.00 (20.51) 10.10** (A,B > C)
PCS 48.39 (8.52) 52.97 (17.20) 40.78 (12.50) 20.06** (B > A > C)
MCS 49.73 (8.19) 49.73 (12.00) 46.34 (12.51) 3.23* (A > C)
Abdominal symptom   6.06 (1.30) 5.75(1.33) 1.31
Fatigue   5.38(1.56) 4.78(1.38) 2.31*
Systemic symptoms   5.71(1.09) 4.98(1.06) 3.88**
Activity   5.12(1.51) 5.21(1.52) 1.01
Emotional function   5.78(1.16) 5.02(1.42) 3.30**
Worry   6.10(1.33) 5.95(1.16) 0.71
  1. *p < 0.05, **p < 0.01; Age and gender were matched; SD: standard deviation; post-hoc multiple comparison by Scheffe’ method.